ABU J. M. SADEQUE,GLEN MARQUEZ,JEFFREY EDWARDS,JUERG LEHMANN,MICHAEL E. MORGAN,ROBERT M. JONES,SUN HEE KIM,WEICHAO CHEN
申请号：
BR112013008100
公开号：
BR112013008100A2
申请日:
2011.09.21
申请国别(地区):
BR
年份:
2016
代理人:
摘要：
gpr19 receptor modulators and the treatment of disorders related thereto. The present invention relates to gpr119 receptor agonists: 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluoropropan-2-yl) -1,2,4-oxadiazole) 5-yl) piperidin-1-yl) pyrimidin-4-ylamino) -N, n-dimethylbenzamide； 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluoropropan-2-yl) -1,2,4-oxadiazol-5-yl) piperidin-1-yl) pyrimidin-4 -ylamino) -n-methylbenzamide； and 3-fluoro-4- (5-fluoro-6- (4- (3- (2-fluropropan-2-yl) -1,2,4-oxadiazol-5-yl) piperidin-1-yl) pyrimidin-2-one 4-ylamino) benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, which are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as a dpp-iv inhibitor, a biguanide, an alpha-glucosity inhibitor, an insulin analogue, a sulfonylurea, an sglt2 inhibitor, a meglitinide, a thiazolidinedione, or an antidiabetic peptide analogue, in the treatment of, for example, a disorder selected from: a receptor-related disorder from gpr119: an improved condition by increasing secretion of an incretin； an improved condition by increasing a blood incretin level； a condition characterized by low bone mass； a neurological disorder； a related metabolic disorder； type 2 diabetes； obesity； and complications related to them.moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles. a presente invenção refere-se aos agonistas de receptor de gpr119: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)-n, n-dimetilbenzamida； 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il) pirimidin-4-ilamino)-n-metilbenzamida； e 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluropropan-2-il)-1,2,4-oxadiazol-5-il)piperidin-1-il)pirimidin-4-ilamino)benzamida, e sais, solvatos, e hidratos farmaceuticamente aceitáveis dos mesmos, que são úteis como um único agente farmacêutico ou em combinação com um ou mais agen
